RNA Methylation Enzyme ALKBH5 Drives Cardiac Aging via Glutamine Metabolism
Elevated ALKBH5 in aging hearts strips protective RNA methylation marks, cutting glutamine uptake and accelerating cardiac decline.
Summary
As hearts age, levels of a molecular eraser called ALKBH5 rise, stripping chemical tags called m6A from messenger RNA. This removal reduces a key glutamine transporter (SLC38A3), starving heart muscle cells of glutamine. Without adequate glutamine, mitochondria malfunction, oxidative stress climbs, and the hallmarks of cardiac aging accumulate. Researchers showed that silencing ALKBH5 in young adult mice protected the heart from age-related remodeling and dysfunction, while overexpressing SLC38A3 or simply supplementing with glutamine produced similar protective effects. Critically, the intervention only worked when started before significant aging had occurred — suggesting a prevention window rather than a reversal strategy. This research identifies the ALKBH5–SLC38A3 axis as a promising target for slowing cardiac aging at the epigenetic and metabolic level.
Detailed Summary
Cardiac aging is among the most consequential biological processes driving mortality and disability in older adults, yet its molecular underpinnings remain incompletely understood. This study, published online ahead of print in Circulation, illuminates a previously uncharacterized pathway linking RNA epigenetics to heart muscle metabolism and aging.
The researchers focused on N6-methyladenosine (m6A), the most abundant internal modification on messenger RNA, which regulates how transcripts are read, stabilized, and translated. Using physiologically aged mice, a paraquat-induced cardiac aging model, and senescent cardiomyocyte cultures, they found that ALKBH5 — an enzyme that removes m6A marks — is significantly upregulated in aging hearts. The consequence is a broad reduction in m6A levels across cardiac transcripts.
Through methylated RNA immunoprecipitation sequencing and functional screening, the team identified SLC38A3, a glutamine transporter, as a critical downstream target. ALKBH5-mediated demethylation reduced SLC38A3 mRNA stability via a YTHDC2-dependent mechanism, cutting intracellular glutamine levels. Glutamine is essential for mitochondrial energy production and antioxidant defenses; its depletion impaired mitochondrial homeostasis and amplified oxidative stress, accelerating senescence-associated phenotypes.
Silencing ALKBH5 with AAV9-delivered shRNA initiated in young adult mice attenuated aging-related cardiac remodeling and preserved function. Notably, the same intervention begun in already-aged hearts failed to reverse established damage — a critical caveat for translational thinking. Independently, overexpressing SLC38A3 or supplementing with glutamine also reduced cardiac aging phenotypes in vivo, confirming the pathway's causal role.
These findings position the ALKBH5–SLC38A3 axis as a tractable target for preventing cardiac aging. For clinicians and researchers, they also highlight glutamine metabolism as an underappreciated lever in cardiovascular aging biology. Limitations include the preclinical nature of the work and reliance on the abstract alone for this summary.
Key Findings
- ALKBH5 rises in aging hearts, erasing m6A RNA marks and driving cardiac dysfunction via metabolic disruption.
- Knockdown of ALKBH5 in young adult mice prevented age-related cardiac remodeling and preserved heart function.
- ALKBH5 demethylation reduces SLC38A3 glutamine transporter expression, starving cardiomyocytes of a critical metabolite.
- Glutamine supplementation alone reduced cardiac aging phenotypes in mouse models, a potentially accessible intervention.
- ALKBH5 silencing initiated in already-aged hearts did not reverse established damage, underscoring a prevention window.
Methodology
The study used physiologically aged mice, paraquat-induced cardiac aging models, and senescent cardiomyocyte cultures. ALKBH5 expression was modulated in vivo via AAV9-shRNA and in vitro via siRNA; downstream targets were identified using methylated RNA immunoprecipitation sequencing and functional screening. Cardiac phenotyping included echocardiography, histology, and immunostaining.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access. All experiments were conducted in mice, and translation to humans remains unproven. Intervention efficacy was strictly preventive — no reversal of established cardiac aging was observed when treatment began late.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: